SQZ Biotechnologies Company SQZ
Set alert
0.44 0.00 0.00%
As of Jul 3, 1:00 PM ET
0.38 Day range 0.5678
52-week range unavailable
- Open
- 0.40995
- Prev close
- 0.435
- Mkt cap
- 12.83M
- Vol
- 30.14M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.38
- High
- 0.5678
- Forward P/E
- -0.62
- Beta
- 2.71
- Short ratio
- 27.26
- Inst. own
- 66.58%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 3, 2023
- 50-d avg
- 0.509346
- 200-d avg
- 1.13
- 1y target
- 19.00
Analyst view
Consensus: buy
Buy
Price target (mean) 19.00 +4267.8% upside
Now 0.435
- Target (low)
- 4.00
- Target (mean)
- 19.00
- Target (high)
- 34.00
Recommendation trend
- 1 month ago 3
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.60 | -0.66 – -0.54 | -0.78 | +23.1% | 2.25M | -30.0% | 2 |
| Next quarter | -0.75 | -1.00 – -0.50 | -0.77 | +2.6% | 2.95M | -30.6% | 2 |
| Current year | -2.68 | -3.24 – -2.12 | -2.76 | +2.9% | 19.45M | -9.4% | 2 |
| Next year | -0.70 | -0.83 – -0.58 | -2.68 | +73.9% | 73.70M | +278.9% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Dec 1, 2022 | Chardan Capital | Maintained | — | Buy |
| Dec 1, 2022 | B of A Securities | Downgrade | Buy | Underperform |
| Nov 10, 2022 | Chardan Capital | Maintained | — | Buy |
| Oct 20, 2022 | HC Wainwright & Co. | Initiated | — | Buy |
| Oct 6, 2022 | BTIG | Maintained | — | Buy |
| May 25, 2022 | Chardan Capital | Initiated | — | Buy |
| Jan 8, 2021 | Evercore ISI Group | Initiated | — | Outperform |
| Nov 24, 2020 | B of A Securities | Initiated | — | Buy |
| Nov 24, 2020 | BTIG | Initiated | — | Buy |
| Nov 24, 2020 | Stifel | Initiated | — | Buy |